We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.54%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$855M
AUM Growth
+$208M
Cap. Flow
+$133M
Cap. Flow %
15.53%
Top 10 Hldgs %
33.51%
Holding
104
New
21
Increased
54
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$28.3M
2
STJ
St Jude Medical
STJ
+$21.6M
3
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$9.49M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$9.39M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$9.37M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$13.2M
2
GILD icon
Gilead Sciences
GILD
+$11.2M
3
PCRX icon
Pacira BioSciences
PCRX
+$9.89M
4
ATHN
Athenahealth, Inc.
ATHN
+$8.92M
5
CAH icon
Cardinal Health
CAH
+$6.91M

Sector Composition

Rank Sector Weight
1 Healthcare 73.14%
2 Financials 1.36%
3 Technology 0.94%
4 Industrials 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVDQ
51
DELISTED
Novadaq Technologies Inc.
NVDQ
$6.27M 0.73%
377,500
+67,500
+22% +$964K
RLYP
52
DELISTED
RELYPSA INC COM
RLYP
$5.79M 0.68%
188,000
+43,000
+30% +$1.02M
ILMN icon
53
Illumina
ILMN
$28.4B
$5.63M 0.66%
31,354
-6,682
-18% -$1.18M
STE icon
54
Steris
STE
$23.1B
$5.25M 0.61%
+81,000
New +$5M
CNXR
55
DELISTED
Connecture, Inc.
CNXR
$4.99M 0.58%
+554,225
New +$4.97M
WCG
56
DELISTED
Wellcare Health Plans, Inc.
WCG
$4.92M 0.58%
60,000
-16,250
-21% -$1.13M
ACHN
57
DELISTED
Achillion Pharmaceuticals
ACHN
$4.47M 0.52%
+365,000
New +$4.46M
ZSPH
58
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$4.45M 0.52%
107,000
+15,000
+16% +$592K
TNDM icon
59
Tandem Diabetes Care
TNDM
$1.56B
$4.45M 0.52%
35,000
+7,300
+26% +$1.01M
PBYI icon
60
Puma Biotechnology
PBYI
$454M
$4.4M 0.51%
23,250
+2,750
+13% +$610K
TBPH icon
61
Theravance Biopharma
TBPH
$877M
$4.33M 0.51%
290,000
+134,500
+86% +$2.34M
PRTA icon
62
Prothena Corp
PRTA
$450M
$4.2M 0.49%
202,500
– –
KYNB
63
Kyntra Bio
KYNB
$29.4M
$4.14M 0.48%
+6,052
New +$3.89M
JAZZ icon
64
Jazz Pharmaceuticals
JAZZ
$16.7B
$4.09M 0.48%
25,000
+6,750
+37% +$1.12M
AERI
65
DELISTED
Aerie Pharmaceuticals
AERI
$4.09M 0.48%
140,000
+40,700
+41% +$1.03M
AGN
66
DELISTED
Allergan Inc
AGN
$3.93M 0.46%
18,500
-4,250
-19% -$845K
CHRS icon
67
Coherus Oncology
CHRS
$196M
$3.92M 0.46%
+240,051
New +$3.39M
CYBX
68
DELISTED
CYBERONICS INC
CYBX
$3.79M 0.44%
68,000
+1,000
+1% +$52.3K
NVAX icon
69
Novavax
NVAX
$1.31B
$3.77M 0.44%
31,750
+3,000
+10% +$314K
CTLT
70
DELISTED
CATALENT, INC.
CTLT
$3.73M 0.44%
133,600
-67,400
-34% -$1.77M
CO
71
DELISTED
Global Cord Blood Corporation
CO
$3.71M 0.43%
822,000
+27,000
+3% +$128K
REGN icon
72
Regeneron Pharmaceuticals
REGN
$80.8B
$3.69M 0.43%
+9,000
New +$3.54M
WX
73
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
$3.62M 0.42%
107,500
+11,000
+11% +$389K
INFI
74
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$3.55M 0.41%
210,000
– –
EPZM
75
DELISTED
Epizyme, Inc
EPZM
$3.42M 0.4%
181,500
+50,500
+39% +$1.18M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Rock Springs Capital Management held 104 positions worth $855M, up 32% from $646M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management deployed $133M of net new capital in Q4 2014, opening 21 new positions and adding to 54 existing holdings. Its largest new stake was COVIDIEN PLC COM SHS NEW (IRELAND): 295,000 shares worth $30.2M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 79% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Gilead Sciences, an estimated $11.2M trimmed.

  • Rock Springs Capital Management's largest Q4 2014 buy was COVIDIEN PLC COM SHS NEW (IRELAND): 295,000 shares worth $30.2M.
  • Rock Springs Capital Management added most to Acadia Healthcare in Q4 2014, an estimated $7.38M increase.
  • Rock Springs Capital Management's biggest Q4 2014 reduction was Gilead Sciences, cutting an estimated $11.2M.
  • Rock Springs Capital Management fully exited Thermo Fisher Scientific in Q4 2014, selling an estimated $13.2M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $855M portfolio in Q4 2014.
  • Rock Springs Capital Management opened 21 new positions and closed 11 in Q4 2014.
  • Rock Springs Capital Management's portfolio value rose 32% quarter-over-quarter to $855M.

Based on Rock Springs Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.